Periodic Reporting for period 2 - GlucoBeam (GlucoBeam: A portable device for pain-free glucose self-monitoring in diabetic patients)
Periodo di rendicontazione: 2018-03-01 al 2020-11-30
RSP’s proprietary non-invasive SMBG technology relies on the capabilities of Raman spectroscopy for directly detecting individual substances, refined by a unique critical depth optical scanning to collect glucose signals from the right tissue depth range, thus avoiding sources of errors during the measurement. Our device will enable DM patients to test their glucose levels in around 30 seconds and as often as desired – at no added cost or pain – thereby empowering them to better manage their treatment and minimizing the risk for acute complications.
The overall objective of the project is to undertake all required miniaturization activities to transform RSP System’s current tabletop prototype for non-invasive glucose monitoring into a lunchbox-sized system and demonstrate its performance in a large clinical trial to thoroughly document its performance. In addition, the project focus on preparing for commercial exploitation, which will enable RSP systems to penetrate the multi-billion diabetes glucose monitoring market.
Main results include:
- Development of cost optimized product specifications and design plans for miniaturization
- Mobile app architecture lay-out and user-interface design with beta version ready for demo activities
- Optimized data analysis algorithms and improved calibration model
- Established strategic partnering with 3 leading hospitals for pilot trials in Denmark and Germany
- Implementation of quality management system and preparing for ISO 13485-certification
Our strategy to bring an adjunctive device to the market allows both to shorten time-to-market and to rapidly monetize our disruptive technology, empowering RSP to cover its medium term innovation strategy. In sum, our non-invasive device is targeted at a billion global market and its commercialization will represent an aggregate turnover of approx. €253 million over the 5 years post-project. It has the potential to reach double digit billion savings for EU healthcare system and will lead to significantly improved life quality for diabetes patients.